... Food and Drug Administration (FDA) has approved two beta-amyloid therapies for treating the root cause of Alzheimer’s disease: Donanemab-azbt (Kisunla) Lecanemab-irmb (Leqembi) A third beta-amyloid therapy, aducanumab, was approved in 2021 but was withdrawn by its manufacturer in 2024 to focus on other Alzheimer’s treatments. ...
... Food and Drug Administration (FDA) has approved two beta-amyloid therapies for treating the root cause of Alzheimer’s disease: Donanemab-azbt (Kisunla) Lecanemab-irmb (Leqembi) A third beta-amyloid therapy, aducanumab, was approved in 2021 but was withdrawn by its manufacturer in 2024 to focus on other Alzheimer’s treatments. ...
... Lecanemab (Leqembi) was granted FDA approval in January 2023. Lecanemab also targets amyloid plaques in the brain. Donanemab (Kisunla) is another treatment that targets amyloid plaques in the brain. It received FDA approval in July 2024. ...
... Lecanemab (Leqembi) was granted FDA approval in January 2023. Lecanemab also targets amyloid plaques in the brain. Donanemab (Kisunla) is another treatment that targets amyloid plaques in the brain. It received FDA approval in July 2024. ...
Join